SRR25617853
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.620
- INTERFERON_GAMMA_RESPONSE+0.560
- ALLOGRAFT_REJECTION+0.520
- IL6_JAK_STAT3_SIGNALING+0.440
- PANCREAS_BETA_CELLS+0.370
- COMPLEMENT+0.310
- KRAS_SIGNALING_DN+0.290
- INFLAMMATORY_RESPONSE+0.260
- COAGULATION+0.250
- KRAS_SIGNALING_UP+0.220
Top 10 suppressed
- MYC_TARGETS_V2-0.520
- MYC_TARGETS_V1-0.470
- E2F_TARGETS-0.460
- G2M_CHECKPOINT-0.450
- MITOTIC_SPINDLE-0.440
- PROTEIN_SECRETION-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.400
- MTORC1_SIGNALING-0.390
- TGF_BETA_SIGNALING-0.390
- UV_RESPONSE_DN-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-4Z-AA7Q-01A-11R-A39I-07 | — | — | 0.899 |
| 2 | SRR2778078 | — | — | 0.895 |
| 3 | SRR8518255 | — | D | 0.890 |
| 4 | TCGA-44-2657-01A-01R-1107-07 | — | cohortA1 | 0.883 |
| 5 | TCGA-5L-AAT1-01A-12R-A41B-07 | — | A | 0.879 |
| 6 | SRR8518409 | — | D | 0.878 |
| 7 | SRR8518166 | — | D | 0.873 |
| 8 | MNG450 | — | — | 0.871 |
| 9 | MDT-AP-0377 | Med | Medulloblastoma | 0.869 |
| 10 | 94b2af92-0cfc-40b2-977d-6bd0fa4440d9 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.620 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.040 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| APOPTOSIS | 0.010 | Idelalisib | — uncovered |